Acumen Pharmaceuticals, Inc. (ABOS)Healthcare | Biotechnology | Newton, United States | NasdaqGS
2.84 USD
+0.02
(0.709%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:22 a.m. EDT
Acumen Pharmaceuticals is a classic 'earnings play' in about a month, with a clear short-term bullish setup driven by volume at the $2.50 strike anticipating upward momentum, but fundamentally weak with negative earnings, high risk, and zero dividend yield. While analysts see a strong buy, the long-term fundamentals are surprising. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.089017 |
| AutoARIMA | 0.089090 |
| AutoETS | 0.089123 |
| AutoTheta | 0.091587 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.92 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.350 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 44.457 |
| Market Cap | 205,084,240 |
| Forward P/E | -2.04 |
| Beta | 0.34 |
| Website | https://acumenpharm.com |
As of April 19, 2026, 12:22 a.m. EDT: Near-term call volume (April 17) is heavily skewed toward the $2.50 strike (ATM) with a +77.3% volume increase compared to puts, indicating a bullish bias for the immediate earnings week. However, deep in-the-money put positioning shows high Open Interest (OI) at the $5.00 strike across July and October expirations, acting as a strong resistance ceiling. The April 17 call IV is relatively high (3.0) while puts are slightly lower (2.81), suggesting speculators are pricing in a sharp move up to $2.50 but capping upside at $5.00.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.892057 |
| Address1 | 1,210-1220 Washington St. |
| Address2 | Suite 210 |
| All Time High | 26.98 |
| All Time Low | 0.855 |
| Ask | 2.87 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 418,560 |
| Average Daily Volume3 Month | 900,752 |
| Average Volume | 900,752 |
| Average Volume10Days | 418,560 |
| Beta | 0.336 |
| Bid | 2.77 |
| Bid Size | 5 |
| Board Risk | 6 |
| Book Value | 1.163 |
| City | Newton |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.84 |
| Current Ratio | 4.074 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.99 |
| Day Low | 2.82 |
| Debt To Equity | 44.457 |
| Display Name | Acumen Pharmaceuticals |
| Earnings Call Timestamp End | 1,774,526,400 |
| Earnings Call Timestamp Start | 1,774,526,400 |
| Earnings Timestamp | 1,774,528,200 |
| Earnings Timestamp End | 1,778,589,000 |
| Earnings Timestamp Start | 1,778,589,000 |
| Ebitda | -123,774,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.966 |
| Enterprise Value | 119,530,232 |
| Eps Current Year | -1.88296 |
| Eps Forward | -1.39216 |
| Eps Trailing Twelve Months | -2.0 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.779 |
| Fifty Day Average Change | 0.06099987 |
| Fifty Day Average Change Percent | 0.021950295 |
| Fifty Two Week Change Percent | 189.20569 |
| Fifty Two Week High | 3.6 |
| Fifty Two Week High Change | -0.76 |
| Fifty Two Week High Change Percent | -0.21111111 |
| Fifty Two Week Low | 0.951 |
| Fifty Two Week Low Change | 1.8889999 |
| Fifty Two Week Low Change Percent | 1.9863302 |
| Fifty Two Week Range | 0.951 - 3.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,625,146,200,000 |
| Float Shares | 40,719,330 |
| Forward Eps | -1.39216 |
| Forward P E | -2.0399952 |
| Free Cashflow | -75,107,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 60 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -104,885,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11261 |
| Held Percent Institutions | 0.63094 |
| Implied Shares Outstanding | 72,212,758 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-01 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts. |
| Long Name | Acumen Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 205,084,240 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_8539521 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -121,335,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 205,806,360 |
| Number Of Analyst Opinions | 5 |
| Open | 2.83 |
| Operating Cashflow | -115,538,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 344 4190 |
| Pre Market Change | 0.0400002 |
| Pre Market Change Percent | 1.4084578 |
| Pre Market Price | 2.88 |
| Pre Market Time | 1,776,769,950 |
| Previous Close | 2.82 |
| Price Eps Current Year | -1.5082636 |
| Price Hint | 4 |
| Price To Book | 2.4419603 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.928 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.02 |
| Regular Market Change Percent | 0.709219 |
| Regular Market Day High | 2.99 |
| Regular Market Day Low | 2.82 |
| Regular Market Day Range | 2.82 - 2.99 |
| Regular Market Open | 2.83 |
| Regular Market Previous Close | 2.82 |
| Regular Market Price | 2.84 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 298,785 |
| Return On Assets | -0.4278 |
| Return On Equity | -0.96204 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 72,212,758 |
| Shares Percent Shares Out | 0.0146 |
| Shares Short | 1,055,415 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 960,875 |
| Short Name | Acumen Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0187 |
| Short Ratio | 1.21 |
| Source Interval | 15 |
| State | MA |
| Symbol | ABOS |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.4 |
| Target Median Price | 8.0 |
| Total Cash | 116,865,000 |
| Total Cash Per Share | 1.618 |
| Total Debt | 31,311,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.016725 |
| Two Hundred Day Average Change | 0.82327485 |
| Two Hundred Day Average Change Percent | 0.40822363 |
| Type Disp | Equity |
| Volume | 298,785 |
| Website | https://acumenpharm.com |
| Zip | 2,465 |